ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2629

Longitudinal Analysis of Persistent Positivity of Antiphospholipid Antibodies in Systemic Lupus Erythematosus

Michelle Petri1, Mertcan Avci2 and Laurence S Magder3, 1Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 2Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey, 3Epidemiology and Preventive Medicine, University of MD, Baltimore, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Antiphospholipid antibodies and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Systemic Lupus Erythematosus – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: ‘Persistent positivity” has been a part of laboratory criteria for antiphospholipid syndrome classification criteria and requires two positive tests. We investigated the clinical utility of multiple measures of lupus anticoagulant and anticardiolipin antibodies in SLE patients over the course of clinical care.

Methods: We studied 943 SLE patients in a large single-center cohort who were assessed for lupus anticoagulant (by dRVVT) and anticardiolipin (aCL) IgG, IgM and IgA at at least 10 clinic visits. For each patient, we determined the percent of follow-up time positive for antiphospholipid antibodies and assessed the relationship between this percent and lifetime history of thrombosis.

Results: Among those ever positive for antiphospholipid antibodies, the large majority of SLE patients were positive less than 25% of time followed (Table 1).

Table 1. Most SLE Patients are Positive for aCL or dRVVT Less Than 25% of time followed

aPL definition

Proportion of time during follow-up in which aPL were positive

0

>0-0.25

>0.25-0.5

>0.5-0.75

>0.75

aCL IgG>=20

728 (77%)

149 (16%)

33 (4%)

15 (2%)

18 (2%)

aCL IgG>=40

856 (91%)

66 (7%)

11 (1%)

5 (1%)

5 (1%)

aCL IgM>=20

693 (73%)

185 (20%)

26 (3%)

14 (1%)

25 (3%)

aCL IgM>=40

829 (88%)

85 (9%)

14 (1%)

7 (1%)

8 (1%)

aCL IgA>=20

861 (91%)

69 (7%)

9 (1%)

0 (0%)

4 (<1%)

aCL IgA>=40

909 (96%)

29 (3%)

2 (<1%)

1 (<1%)

2 (<1%)

dRVVT>45

564 (60%)

273 (29%)

49 (5%)

22 (2%)

35 (4%)

Any of above

378 (40%)

369 (39%)

90 (10%)

35 (4%)

71 (8%)

For the lupus anticoagulant, there was a progressively increasing association of history of thrombosis with greater proportion of time positive (Table 2). For anticardiolipin antibodies or lupus anticoagulant, even those with relatively infrequent positive measures had a greater likelihood of a history of thrombosis than those who were never positive.

Table 2: Associations of aCL and dRVVT with Thrombosis.

aPL Definition

Proportion of time with aPL

Any Thrombosis

N

Number (%) with Thrombosis

RR1 (95% CI)

P-value

aCL IgG>20

0

728

138 (19%)

1.0 (Ref)

>0-0.25

149

46 (31%)

1.7 (1.2, 2.3)

0.0034

>0.25-0.5

33

9 (27%)

1.5 (0.9, 2.5)2

0.13

>0.5-.75

15

1 (7%)

>0.75

18

7 (39%)

aCL IgG>40

0

856

175 (20%)

1.0 (Ref)

>0-0.25

66

20 (30%)

1.5 (0.9, 2.3)

0.11

>0.25-0.5

11

2 (18%)

1.8 (0.8, 4.0)2

0.16

>0.5-.75

5

2 (40%)

>0.75

5

2 (40%)

aCL IgM>20

0

693

138 (20%)

1.0 (Ref)

>0-0.25

185

41 (22%)

1.2 (0.9, 1.8)

0.24

>0.25-0.5

26

8 (31%)

1.7 (1.1, 2.7)2

0.020

>0.5-.75

14

3 (21%)

>0.75

25

11 (44%)

aCL IgM>40

0

829

166 (20%)

1.0 (Ref)

>0-0.25

85

24 (28%)

1.4 (0.9, 2.2)

0.099

>0.25-0.5

14

4 (29%)

2.2 (1.2, 4.0)2

0.012

>0.5-.75

7

3 (43%)

>0.75

8

4 (50%)

aCL IgA>20

0

861

177 (21%)

1.0 (Ref)

>0-0.25

69

18 (26%)

1.1 (0.7, 1.9)

0.59

>0.25-0.5

9

4 (44%)

2.1 (0.9, 4.7)2

0.079

>0.5-.75

0

>0.75

4

2 (50%)

aCL IgA>40

0

909

190 (21%)

1.0 (Ref)

>0-0.25

29

9 (31%)

1.3 (0.7, 2.5)

0.45

>0.25-0.5

2

1 (50%)

1.7 (0.4, 6.8)2

0.46

>0.5-.75

1

0 (0%)

>0.75

2

1 (50%)

dRVVT>45

0

564

91 (16%)

1.0 (Ref)

>0-0.25

273

68 (25%)

1.5 (1.1, 2.0)

0.018

>0.25-0.5

49

19 (39%)

2.7 (1.6, 4.43)

0.0001

>0.5-.75

22

8 (36%)

2.2 (1.1, 4.5)

0.033

>0.75

35

15 (43%)

3.4 (2.0, 5.9)

<0.0001

Any of the above

0

378

60 (16%)

1.0 (Ref)

>0-0.25

369

81 (22%)

1.3 (1.0, 1.9)

0.095

>0.25-0.5

90

25 (28%)

1.8 (1.1, 2.8)

0.016

>0.5-.75

35

8 (23%)

1.5 (0.7, 3.1)

0.31

>0.75

71

27 (38%)

2.6 (1.6, 4.1)

<0.0001

1 Based on a Cox Model. 2 RR and p-value are for >0.25-0.5, >0.5-0.75, and >0.75 groups combined compared to Reference.

Conclusion: In SLE, antiphospholipid antibody positivity tends to be at a minority of visits. Yet, even those with sporadic positive findings are at increased risk of thrombosis. This contrasts with the natural history of primary antiphospholipid antibodies/syndrome. These data strongly support prophylactic therapy in those who are sporadically positive.


Disclosure: M. Petri, EMD Serono, 5,Exagen, 2,Janssen, 5,GSK, 5,AstraZeneca, 2,Inova Diagnostic, 5,Novartis, 5,Amgen Inc., 5,Decision Resources, 5,Medscape, 5,Eli Lilly and Co., 5,Quintiles, 5; M. Avci, None; L. S. Magder, None.

To cite this abstract in AMA style:

Petri M, Avci M, Magder LS. Longitudinal Analysis of Persistent Positivity of Antiphospholipid Antibodies in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/longitudinal-analysis-of-persistent-positivity-of-antiphospholipid-antibodies-in-systemic-lupus-erythematosus/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-analysis-of-persistent-positivity-of-antiphospholipid-antibodies-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences